Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $3.03, $0.10 worse than the analyst estimate of $3.13. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $8.08 billion. Gilead Sciences reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

Earnings Guidance Hot Earnings

Gilead Sciences (GILD) PT Lowered to $118 at UBSApril 29, 2016 8:27 AM Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO CapitalApril 29, 2016 7:40 AM Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C SalesApril 29, 2016 7:30 AM Maxim Group Downgrades Gilead Sciences (GILD) to HoldApril 29, 2016 7:06 AM Gilead Sciences (GILD) PT Trimmed to $123 at Leerink PartnersApril 29, 2016 6:50 AM Gilead Sciences Announces First Quarter 2016 Financial ResultsApril 28, 2016 4:02 PM